These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 2597694)

  • 1. Phosphate promotes glycation of antithrombin III which interferes with heparin binding.
    Hall PK; Roberts RC
    Biochim Biophys Acta; 1989 Dec; 993(2-3):217-23. PubMed ID: 2597694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of heparin-catalyzed human antithrombin III activity by nonenzymatic glycosylation. Possible role in fibrin deposition in diabetes.
    Brownlee M; Vlassara H; Cerami A
    Diabetes; 1984 Jun; 33(6):532-5. PubMed ID: 6724150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Demonstration of altered antithrombin III activity due to nonenzymatic glycosylation at glucose concentration expected to be encountered in severely diabetic patients.
    Villanueva GB; Allen N
    Diabetes; 1988 Aug; 37(8):1103-7. PubMed ID: 3391345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S protein modulates the heparin-catalyzed inhibition of thrombin by antithrombin III. Evidence for a direct interaction of S protein with heparin.
    Preissner KT; Müller-Berghaus G
    Eur J Biochem; 1986 May; 156(3):645-50. PubMed ID: 3699029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change.
    Turk B; Brieditis I; Bock SC; Olson ST; Björk I
    Biochemistry; 1997 Jun; 36(22):6682-91. PubMed ID: 9184148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic analysis of various heparin fractions and heparin substitutes in the thrombin inhibition reaction.
    Pletcher CH; Cunningham M; Nelsestuen GL
    Biochim Biophys Acta; 1985 Jan; 838(1):106-13. PubMed ID: 2578296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dependence of the rate of thrombin/antithrombin III reaction upon the turnover rate of a catalytic amount of heparin.
    Oshima G
    Chem Pharm Bull (Tokyo); 1989 Aug; 37(8):2155-9. PubMed ID: 2598315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyridoxylation of essential lysines in the heparin-binding site of antithrombin III.
    Pecon JM; Blackburn MN
    J Biol Chem; 1984 Jan; 259(2):935-8. PubMed ID: 6420409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-enzymatic glycation of antithrombin III in vitro.
    Sakurai T; Boissel JP; Bunn HF
    Biochim Biophys Acta; 1988 Mar; 964(3):340-7. PubMed ID: 3349100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium inhibits the heparin-catalyzed antithrombin III/thrombin reaction by decreasing the apparent binding affinity of heparin for thrombin.
    Speight MO; Griffith MJ
    Arch Biochem Biophys; 1983 Sep; 225(2):958-63. PubMed ID: 6625618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anticoagulating activity and lytic action of the heparin-antithrombin III and antithrombin III-heparin-thrombin complexes on non-stabilized fibrin].
    Kudriashov BA; Pastorova VE; Liapina LA
    Biokhimiia; 1981 Nov; 46(11):2024-9. PubMed ID: 7317530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding.
    Jørgensen M; Petersen LC; Thorsen S
    J Lab Clin Med; 1984 Aug; 104(2):245-56. PubMed ID: 6747440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dependence of antithrombin III and thrombin binding stoichiometries and catalytic activity on the molecular weight of affinity-purified heparin.
    Nesheim M; Blackburn MN; Lawler CM; Mann KG
    J Biol Chem; 1986 Mar; 261(7):3214-21. PubMed ID: 3949769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of NaC1 on inactivation of bovine thrombin by antithrombin III in the presence of low affinity-heparin or dextran sulfate.
    Oshima G; Nagasawa K
    Thromb Res; 1986 Feb; 41(3):361-72. PubMed ID: 2422780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding of heparin to human antithrombin III as studied by measurements of tryptophan fluorescence.
    Einarsson R; Andersson LO
    Biochim Biophys Acta; 1977 Jan; 490(1):104-11. PubMed ID: 65182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the kinetic behavior of human and bovine proteins in the heparin-catalyzed antithrombin III/thrombin reaction.
    Cunningham MT; Nelsestuen GL
    Biochim Biophys Acta; 1987 Jan; 911(1):66-70. PubMed ID: 3790599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
    Weitz JI; Hudoba M; Massel D; Maraganore J; Hirsh J
    J Clin Invest; 1990 Aug; 86(2):385-91. PubMed ID: 2384594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of surface charge on the accelerating action of heparin on the antithrombin III-inhibited activity of alpha-thrombin.
    Heuck CC; Schiele U; Horn D; Fronda D; Ritz E
    J Biol Chem; 1985 Apr; 260(8):4598-603. PubMed ID: 3988727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of different ions on the interactions of heparin with bovine antithrombin III and thrombin.
    Oshima G; Nagasawa K
    Thromb Res; 1986 May; 42(3):375-82. PubMed ID: 3715809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombin III Northwick Park: demonstration of an inactive high MW complex with increased affinity for heparin.
    Lane DA; Flynn A; Ireland H; Erdjument H; Samson D; Howarth D; Thompson E
    Br J Haematol; 1987 Apr; 65(4):451-6. PubMed ID: 3580302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.